Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement

David W. Self, David A. Karanian, Jennifer J. Spencer

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Selective D1 dopamine agonists represent a potential pharmacotherapy for the treatment of cocaine addiction. Here we report that systemic injections of the novel D1 agonist ABT-431 lack the ability to induce cocaine-seeking behavior, and completely attenuate the ability of cocaine to induce this behavior in rats tested in a reinstatement paradigm. Similar doses suppress the initiation of cocaine self-administration, and produce an extinction-like response pattern in animals that subsequently initiate self-administration, without altering responding maintained by food pellets. There was no tolerance to this effect over 4 days of testing. The results suggest that ABT-431 attenuates the motivation to seek cocaine, and masks the reinforcing effects of cocaine during self-administration. The profile of ABT-431 is similar to the behavioral effects of other structurally distinct D1 agonists, and is consistent with the desired profile of a 'methadone-like' compound for cocaine addiction.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalAnnals of the New York Academy of Sciences
StatePublished - 2000

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Effects of the novel D<sub>1</sub> dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement'. Together they form a unique fingerprint.

Cite this